Loading data for JANX — first visit, this takes a few seconds.

Janux Therapeutics, Inc. (JANX)

NasdaqGM: JANX · Real-Time Price · USD

18.89

+0.67 (3.68%)

At close: Sep 11, 2026, 3:59 PM

18.86

-0.16%

After-hours: 7:30 PM

Alert

The price, the headline numbers and the latest news, in one place.

3.68% (1D)

Bid	11.53
Market Cap	1.15B
Revenue (ttm)	24M
Net Income (ttm)	-103M
	2.51
	-1.64
	n/a
	-7.2
P/B (ttm)	1.24
P/S (ttm)	48.12
Earnings Date	Nov 5, 2026

Ask	20.54
Volume	980,541
Avg. Volume (20D)	978,390
Open	18.15
Previous Close	18.22
Day's Range	18.04 - 18.93
52-Week Range	12.12 - 35.34
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About JANX

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 11, 2021

Employees 113

Stock Exchange NasdaqGM

Ticker Symbol JANX

Website https://www.januxrx.com

Full Company Profile

Financial Performance

In 2025, Janux Therapeutics's revenue was 10M, a decrease of -5.55% compared to the previous year's 10.59M. Earnings were -113.63M, an increase of 64.69%.

Financial Statements

Earnings Surprise

Janux Therapeutics has released their quarterly earnings on Aug 6, 2026:

Revenue of $10.27M misses estimates by $0, with Infinity% YoY growth.
EPS of -0.35 misses estimates by -0.06, with 36.36% YoY growth.

Next Earnings Release

Janux Therapeutics, Inc. is scheduled to release its earnings on Nov 5, 2026, during market hours.
Analysts project revenue of ... Upgrade

Why Price Moved

News

2 weeks ago · The Fly

Chipotle downgraded, Darden upgraded: Wall Street's top analyst calls

2 weeks ago · 24/7 Wall St.

Here Are Monday’s Top Wall Street Analyst Research Calls: AstraZeneca, Celestica, Chipotle Mexican Grill, Domino’s Pizza, Fortune Brands, Golar LNG, Jersey Mike’s Subs, Roku, and More

Wall Street analysts reshuffled the deck on Monday with a wave of upgrades, downgrades, and fresh initiations spanning pharma giants, fast-casual chains, and streaming players. Find out which names go...

1 month ago · Simply Wall St.

Janux Therapeutics (JANX) Is Up 7.1% After Reporting Narrower Net Losses And Improved Earnings Profile

In the past, Janux Therapeutics, Inc. reported second-quarter 2026 results showing a net loss of US$21.97 million, or US$0.35 per share, compared with a net loss of US$33.86 million, or US$0.55 per sh...

1 month ago · Zacks

Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates

Janux Therapeutics (JANX) delivered earnings and revenue surprises of -34.62% and -72.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1 month ago · Simply Wall St.

3 Small-Cap Biotech Stocks Pairing Rapid Revenue Growth With High Insider Ownership

Most small-cap biotech stocks are pure clinical bets. These three already have revenue on the books and insiders backing them with their own capital.

Page 1 of 2

Janux Therapeutics, Inc. (JANX)